查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1981685

G蛋白偶联受体市场：按受体分类、治疗领域、应用和最终用户划分－2026-2032年全球市场预测

G-Protein Coupled Receptors Market by Receptor Class, Therapeutic Area, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，G 蛋白偶联受体 (GPCR) 市值将达到 42.3 亿美元，到 2026 年将成长至 45.8 亿美元，复合年增长率为 9.79%，到 2032 年将达到 81.5 亿美元。

主要市场统计数据
基准年 2025 42.3亿美元
预计年份：2026年 45.8亿美元
预测年份 2032 81.5亿美元
复合年增长率 (%) 9.79%

这是一个清晰权威的关于 GPCR 科学和商业化的介绍，将近期技术突破置于治疗和转化背景下进行阐述。

G蛋白偶联受体（GPCR）在细胞讯号传导和治疗方法的创新中占据核心地位，也是药理学上最容易调控的膜蛋白家族之一。过去二十年来，高解析度结构生物学、冷冻电镜和整合计算建模等技术的进步极大地提升了我们阐明受体结构、配体结合模式和讯号传导偏差的能力。这些科学突破催生了多种小分子、胜肽、生物製剂以及不依赖特定作用机制的药物发现平台，进一步推动了针对以往难以靶向的受体亚型的研究。

结构生物学、电脑设计和模态创新如何融合，重新定义 GPCR 标靶药物发现，并重塑全产业的合作模式。

G蛋白偶联受体（GPCR）领域正经历一场变革，这得益于科学、技术和经营模式创新的融合。结构测定方法，特别是冷冻电镜和先进的X射线晶体衍射技术，如今能够提供GPCR-配体复合物的高分辨率图像，从而加速基于结构的药物设计和先导化合物的合理优化。同时，对偏向性激动作用和变构调节的深入理解，正在拓展治疗药物设计的范围，从而实现对下游讯号通路更具选择性的调控，并有可能减少脱靶效应。

我们评估与关税相关的供应链调整和采购环境的波动如何重塑各个相关人员的GPCR研发营运策略。

2025年美国关税政策的变化对GPCR研发相关的供应链、成本结构和筹资策略产生了深远的波动。这种累积影响在专用设备、试剂和实验室耗材的采购方面最为明显，这些耗材通常透过国际供应商采购。进口设备组件和某些特殊化学品的关税增加，推高了进行高解析度结构分析和大规模筛检的实验室的资本支出。因此，采购週期延长，由于各机构需要修改供应商合约以应对成本波动，计划进度可能会因此而延长。

基于全面细分的洞察，描绘受体生物学、临床应用、治疗重点领域和最终用户角色，以促进策略优先排序。

严谨的细分框架揭示了每个受体类别、治疗适应症、开发应用和最终用户的不同机会和风险特征。基于受体类别，此领域涵盖A类视紫质、B类胰泌素、C类代谢型麸胺酸受体、F类捲曲/味觉2受体以及孤儿受体。 A类视紫质再细分为胺基酸受体、趋化素受体、脂质受体、单胺受体、视蛋白受体和胜肽受体等亚类，每种亚类都具有其独特的协调能力和生物学意义。基于治疗领域，该领域的研究活动涵盖心血管疾病、中枢神经系统疾病、胃肠道疾病、发炎、代谢性疾病、肿瘤、疼痛管理和呼吸系统疾病。肿瘤领域的研究进一步细分为乳癌、大肠癌、白血病、肺癌和摄护腺癌，每种癌症都反映了不同的机制和转化途径。

协调科学基础、监管多样性和商业化途径的区域战略考量，以优化全球 GPCR 项目部署。

区域趋势塑造了投资模式、监管预期和企业发展布局，进而影响以G蛋白偶联受体（GPCR）为重点的项目。在美洲，强劲的私人投资、紧密的生物製药公司网络以及重要的学术研究中心为高水准的转化研究活动提供了支持。同时，法律规范也不断演进，优先考虑对高需求治疗方法进行快速核准。在欧洲、中东和非洲，研究能力分散在各个学术中心和专业生物技术丛集中，监管差异正在催生区域特有的临床策略和伙伴关係模式。亚太地区凭藉其快速成长的研发能力、强大的生产能力和日益增多的临床试验设施，正成为从早期药物发现到大规模开发活动等各个环节日益重要的枢纽。

製药巨头、创新生物技术公司、学术先驱和专业服务供应商之间的互动如何塑造 GPCR 开发中的竞争优势。

活跃于G蛋白偶联受体（GPCR）科学研究开发的关键机构包括大型製药企业、创新生物技术公司、学术机构和专业服务供应商。成熟的製药公司凭藉其丰富的临床经验和全球监管专业知识，持续为后期开发和商业化奠定基础。同时，灵活的生技公司正推动新型治疗方法、First-in-Class标靶和专业平台技术的研发。学术机构和公共研究中心仍然是阐明作用机制和早期标靶检验的重要资讯来源，它们常常产生转化科学成果，从而催生衍生公司和许可机会。

为领导者提供切实有效的建议，以加速 GPCR 创新、增强营运韧性并建立与转化优先事项一致的伙伴关係。

产业领导者应采取一系列切实可行的措施，充分利用科学发展势头，同时降低业务风险。首先，他们应优先投资于能够显着缩短转化研究週期的技术，例如基于结构的药物设计、先进的生物物理表征以及人工智慧驱动的配体生成，因为这些技术能够增强决策早期阶段的信心。其次，他们应实现供应商网路多元化，并建立近岸伙伴关係关係，以降低供应链中断和关税成本压力带来的风险，同时检验替代试剂和服务供应商，并确保实验的连续性。

采用透明严谨的调查方法，结合专家访谈、文献整合、结构和临床资料分析以及基于情境的检验。

本研究整合了多种互补的调查方法，以提供可靠且可重复的见解。主要资讯透过对各领域专家的结构化访谈收集，包括学术研究人员、临床首席研究员和产业研发主管，从而对转化研究中的科学重点和挑战进行定性分析。次要研究整合了公开的科学文献、同行评审文章、专利申请、监管文件和临床试验註册信息，以梳理技术进步和临床进展。此外，科学资料库和资源库的分析使得我们能够客观评估结构生物学领域的里程碑事件和模式多样化。

简洁明了且切实可行的结论，将科学进步、实际情况和策略挑战相结合，以实现 GPCR 计画的持续成功。

总之，在结构生物学和电脑辅助设计技术的进步以及对讯号传导复杂性的深入理解的推动下，GPCR领域仍然是治疗方法创新的一个极具前景的领域。这些进展拓宽了标靶候选范围，使得针对从中枢神经系统疾病到肿瘤和代谢性疾病等多种适应症开发更具选择性的疗法成为可能。同时，不断变化的政策环境和供应链趋势也带来了营运方面的挑战，需要策略规划和灵活的伙伴关係。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 G蛋白偶联受体市场（按受体类别划分）

  • A类视紫质
    • 胺基酸受体
    • 趋化素受体
    • 脂质受体
    • 单胺受体
    • 视蛋白受体
    • 胜肽受体
  • B类胰泌素
  • C类代谢型麸胺酸受体
  • F级 薯条 / 口味2
  • 孤儿受体

第九章：G蛋白偶联受体市场：依治疗领域划分

  • 心血管疾病
  • 中枢神经系统疾病
  • 消化系统疾病
  • 发炎
  • 代谢性疾病
  • 肿瘤学
    • 乳癌
    • 结肠癌
    • 白血病
    • 肺癌
    • 摄护腺癌
  • 疼痛管理
  • 呼吸系统疾病

第十章：G蛋白偶联受体市场：依应用领域划分

  • 临床试验
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 诊断
  • 药物发现
  • 临床前开发

第十一章：G蛋白偶联受体市场：依最终用户划分

  • 学术研究机构
  • 合约研究机构
  • 诊断检测实验室
  • 製药和生物技术公司

第十二章：G蛋白偶联受体市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：G蛋白偶联受体市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：G蛋白偶联受体市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国G蛋白偶联受体市场

第十六章：中国G蛋白偶联受体市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abalone Bio, Inc.
  • Abcam PLC
  • Addex Therapeutics
  • Becton, Dickinson and Company
  • BioInvenu,Inc.
  • Cisbio Bioassays SAS
  • Confo Therapeutics
  • Corning Incorporated
  • Crinetics Pharmaceuticals, Inc.
  • Domain Therapeutics SA
  • Enzo Life Sciences, Inc.
  • Escient Pharmaceuticals
  • Eurofins Scientific SE
  • Merck KGaA
  • Molecular Devices, LLC
  • OKYO Pharma, Limited
  • Orion Biotechnology
  • OSE Immunotherapeutics
  • PerkinElmer Inc.
  • Promega Corporation
  • QIAGEN GmbH
  • Septerna
  • Sosei Group Corporation
  • Tectonic Therapeutic
  • Teon Therapeutics, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec
Product Code: MRR-521BAA36EDBA

The G-Protein Coupled Receptors Market was valued at USD 4.23 billion in 2025 and is projected to grow to USD 4.58 billion in 2026, with a CAGR of 9.79%, reaching USD 8.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.23 billion
Estimated Year [2026] USD 4.58 billion
Forecast Year [2032] USD 8.15 billion
CAGR (%) 9.79%

A clear and authoritative introduction to GPCR science and commercialization that situates recent technological breakthroughs within therapeutic and translational contexts

G-protein coupled receptors (GPCRs) occupy a central position in cell signaling and therapeutic innovation, representing one of the most pharmacologically tractable families of membrane proteins. Over the past two decades, technological advances such as high-resolution structural biology, cryo-electron microscopy, and integrative computational modeling have reshaped our ability to interrogate receptor conformations, ligand binding modes, and signaling bias. These scientific breakthroughs have translated into a diversified pipeline of small molecules, peptides, biologics, and modality-agnostic discovery platforms that increasingly target previously intractable receptor subtypes.

In addition, the maturation of translational tools-ranging from chemoproteomics to advanced imaging and human cellular models-has strengthened the bridge between target validation and clinical development. Consequently, stakeholders across pharma, biotechnology, academic institutions, and contract research organizations are prioritizing GPCR portfolios that promise differentiated efficacy, improved safety profiles, and novel mechanisms of action. As a result, stakeholders are recalibrating investment theses, collaboration models, and go-to-market strategies to capture opportunities spanning traditional therapeutic areas and emerging indications.

How converging structural biology, computational design, and modality innovation are redefining GPCR-targeted discovery and reshaping collaboration models across the sector

The GPCR landscape is undergoing transformative shifts driven by converging scientific, technological, and business model innovations. Structural determination methods, particularly cryo-electron microscopy and advanced X-ray crystallography, now enable high-resolution snapshots of GPCR-ligand complexes, which in turn accelerate structure-based drug design and rational optimization of lead compounds. Meanwhile, the growing understanding of biased agonism and allosteric modulation has expanded the therapeutic design space, enabling more selective modulation of downstream signaling pathways and potentially reducing off-target effects.

Concurrently, the integration of artificial intelligence and machine learning into ligand design and virtual screening workflows is improving hit identification efficiency and enabling the rapid exploration of chemical space. At the same time, modality diversification-such as peptide therapeutics, antibody-based GPCR targeting, and intracellular delivery approaches-broadens the ways in which receptors can be selectively engaged. Commercially, these technological shifts catalyze new partnership structures between biotechs and large pharmaceutical companies, and they encourage vertical collaboration with specialized contract research organizations and academic centers that house unique assay platforms and patient-derived models. As these trends continue, competitive advantage will increasingly accrue to organizations that combine deep mechanistic insight with agile translational capabilities.

Assessing how tariff-induced supply chain adjustments and procurement volatility are reshaping operational strategies for GPCR research and development across stakeholder groups

Policy changes in 2025 relating to United States tariffs have introduced ripples that affect supply chains, cost structures, and sourcing strategies relevant to GPCR research and development. The cumulative impact is most visible in the procurement of specialized equipment, reagents, and laboratory consumables that are often sourced through international suppliers. Increased duties on imported instrumentation components and certain specialty chemicals elevate capital expenditure estimates for laboratories undertaking high-resolution structural studies or large-scale screening campaigns. In turn, project timelines can be extended as procurement windows lengthen and institutions reassess vendor agreements to mitigate cost volatility.

Moreover, tariffs influence the economics of outsourcing preclinical and early clinical work to contract research organizations located outside the United States. Organizations that previously relied on cross-border supply resilience are now reconsidering nearshoring or dual-sourcing strategies to maintain continuity. For multinational collaborations, tariff-driven price adjustments may alter the negotiating dynamics of licensing deals and joint development agreements, with partners seeking to share or offset incremental costs. Importantly, these shifts encourage investment in domestic manufacturing of key reagents and in the validation of alternative suppliers, which can strengthen long-term resilience but require short-term capital and operational reallocation. Overall, the tariff environment underscores the need for strategic procurement planning and scenario-based financial modeling when advancing GPCR programs.

Comprehensive segmentation-driven insights that map receptor biology, clinical applications, therapeutic focus areas, and end-user roles to inform strategic prioritization

A rigorous segmentation framework reveals differentiated opportunity and risk profiles across receptor classes, therapeutic indications, development applications, and end users. Based on receptor class, the landscape encompasses Class A Rhodopsin, Class B Secretin, Class C Metabotropic Glutamate, Class F Frizzled/Taste 2, and orphan receptors; within Class A Rhodopsin, subcategories include amino acid receptors, chemokine receptors, lipid receptors, monoamine receptors, opsin receptors, and peptide receptors, each presenting unique ligandability and biological implications. Based on therapeutic area, activities span cardiovascular diseases, central nervous system disorders, gastrointestinal disorders, inflammation, metabolic disorders, oncology, pain management, and respiratory disorders; oncology-focused work further subdivides into breast cancer, colorectal cancer, leukemia, lung cancer, and prostate cancer, reflecting distinct mechanisms and translational pathways.

Based on application, the ecosystem includes clinical trials, diagnostics, drug discovery, and preclinical development, with clinical trials progressing through Phase I, Phase II, and Phase III pathways that carry different evidentiary and operational demands. Based on end user, the market serves academic and research institutes, contract research organizations, diagnostic laboratories, and pharmaceutical and biotech companies, each of which plays discrete roles-from basic target discovery to late-stage development and commercialization. Taken together, this segmentation highlights that strategic priorities and resource allocations should be tailored to receptor biology, therapeutic objectives, and the maturity of the application pipeline, while recognizing that cross-segment collaborations frequently accelerate translational progress.

Regional strategic considerations that reconcile scientific capacity, regulatory diversity, and commercial pathways to optimize global GPCR program deployment

Regional dynamics shape investment patterns, regulatory expectations, and operational footprints that influence GPCR-focused programs. In the Americas, robust private investment, a dense network of biopharma companies, and leading academic centers sustain high levels of translational activity, while regulatory frameworks continue to evolve in ways that prioritize expedited pathways for high-need therapies. In Europe, Middle East & Africa, research strength is distributed across academic hubs and specialized biotech clusters, with regulatory diversity prompting region-specific clinical strategies and partnership models. The Asia-Pacific region combines rapidly expanding R&D capacity with significant manufacturing capabilities and a growing presence of clinical trial sites, making it an increasingly important node for both early-stage discovery and large-scale development activities.

These geographic distinctions inform decisions about where to site key operations, how to structure global development plans, and which regional partnerships to pursue. For example, proximity to specialized assay platforms or patient populations may favor localized collaborations, whereas certain regulatory incentives or cost efficiencies can justify centralized development functions. Thus, effective regional strategies require a granular understanding of local ecosystems, talent pools, reimbursement landscapes, and regulatory pathways, and they often benefit from flexible models that balance global coordination with local execution.

How the interplay among pharmaceutical champions, innovative biotechs, academic pioneers, and specialized service providers is shaping competitive advantage in GPCR development

Leading organizations active in GPCR science and development span large pharmaceutical companies, innovative biotech firms, academic centers, and specialized service providers. Established pharmaceutical companies continue to anchor late-stage development and commercialization through deep clinical experience and global regulatory expertise, while nimble biotech companies advance novel modalities, first-in-class targets, and specialized platform technologies. Academic institutions and public research centers remain critical sources of mechanistic insight and early target validation, often generating the translational science that fuels spinouts and licensing opportunities.

Contract research organizations and diagnostic laboratories provide essential infrastructure for assay development, preclinical testing, and clinical trial execution, enabling sponsors to scale programs rapidly without extending fixed capital commitments. In parallel, a growing cohort of technology providers-focusing on AI-driven discovery, high-throughput screening, single-cell functional assays, and advanced structural biology platforms-are creating complementary capabilities that accelerate hit-to-lead cycles. Strategic partnerships between these actors frequently combine proprietary science with operational scale, and competitive differentiation increasingly derives from integrated value chains that link target biology to clinical execution.

Practical, high-impact recommendations for leaders to accelerate GPCR innovation, shore up operational resilience, and align partnerships with translational priorities

Industry leaders should adopt a set of pragmatic, actionable measures to capitalize on scientific momentum while mitigating operational risks. First, prioritize investment in technologies that materially shorten the translational timeline, such as structure-enabled design, advanced biophysical characterization, and AI-augmented ligand discovery, because these capabilities yield higher confidence at earlier decision points. Second, diversify supplier networks and cultivate nearshore partnerships to reduce vulnerability to supply chain disruptions and tariff-driven cost pressures, while concurrently validating alternative reagents and service providers to maintain experimental continuity.

Third, design modular collaboration frameworks that enable dynamic partnerships with academic labs, biotechs, and CROs, aligning incentives through milestone-based agreements and shared data architectures. Fourth, emphasize translational robustness by incorporating human-relevant models, orthogonal validation methods, and early biomarker strategies that de-risk clinical hypotheses. Fifth, develop portfolio governance that balances high-risk, high-reward targets such as orphan receptors with more de-risked programs grounded in validated receptor classes and therapeutic areas. Taken together, these measures support resilient pipelines that can adapt to scientific advances and policy shifts without sacrificing strategic focus.

Transparent and rigorous research methodology combining expert interviews, literature synthesis, structural and clinical data analysis, and scenario-based validation

This research synthesizes multiple complementary methodologies to deliver robust, reproducible findings. Primary information was gathered through structured interviews with domain experts, including academic investigators, clinical leads, and industry R&D executives, which provided qualitative insight into scientific priorities and translational challenges. Secondary research integrated publicly available scientific literature, peer-reviewed publications, patent filings, regulatory filings, and clinical trial registries to map technological trajectories and clinical progress. In addition, analysis of scientific databases and repositories enabled objective assessment of structural biology milestones and modality diversification.

Analytical techniques included thematic synthesis of expert inputs, cross-validation of findings against independent data sources, and scenario analysis to explore operational and policy contingencies such as tariff impacts. Where appropriate, methodological safeguards-such as triangulation across data types and blinded expert review-were applied to reduce bias and improve the reliability of conclusions. The resulting approach emphasizes transparency in assumptions, traceability of evidence, and a clear linkage between scientific findings and practical business implications, thereby facilitating evidence-based decision-making.

A concise and action-oriented conclusion that synthesizes scientific advances, operational realities, and strategic imperatives for sustained GPCR program success

In conclusion, the GPCR domain remains a fertile ground for therapeutic innovation, driven by advances in structural biology, computational design, and a richer understanding of signaling complexity. These developments expand the repertoire of actionable targets and enable increasingly selective therapeutics across a broad spectrum of indications, from central nervous system disorders to oncology and metabolic disease. At the same time, evolving policy environments and supply chain dynamics introduce operational considerations that demand strategic planning and adaptive partnerships.

Looking ahead, success will favor organizations that integrate mechanistic rigor with translational agility: those that invest in enabling technologies, diversify operational dependencies, and design collaborative models that align scientific discovery with clinical execution. By adopting the strategic recommendations outlined here and grounding decisions in validated evidence, stakeholders can enhance the probability of clinical and commercial success while navigating the practical challenges of a rapidly evolving landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. G-Protein Coupled Receptors Market, by Receptor Class

  • 8.1. Class A Rhodopsin
    • 8.1.1. Amino Acid Receptors
    • 8.1.2. Chemokine Receptors
    • 8.1.3. Lipid Receptors
    • 8.1.4. Monoamine Receptors
    • 8.1.5. Opsin Receptors
    • 8.1.6. Peptide Receptors
  • 8.2. Class B Secretin
  • 8.3. Class C Metabotropic Glutamate
  • 8.4. Class F Frizzled/Taste 2
  • 8.5. Orphan Receptors

9. G-Protein Coupled Receptors Market, by Therapeutic Area

  • 9.1. Cardiovascular Diseases
  • 9.2. Cns Disorders
  • 9.3. Gastrointestinal Disorders
  • 9.4. Inflammation
  • 9.5. Metabolic Disorders
  • 9.6. Oncology
    • 9.6.1. Breast Cancer
    • 9.6.2. Colorectal Cancer
    • 9.6.3. Leukemia
    • 9.6.4. Lung Cancer
    • 9.6.5. Prostate Cancer
  • 9.7. Pain Management
  • 9.8. Respiratory Disorders

10. G-Protein Coupled Receptors Market, by Application

  • 10.1. Clinical Trials
    • 10.1.1. Phase I
    • 10.1.2. Phase II
    • 10.1.3. Phase III
  • 10.2. Diagnostics
  • 10.3. Drug Discovery
  • 10.4. Preclinical Development

11. G-Protein Coupled Receptors Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Diagnostic Laboratories
  • 11.4. Pharmaceutical And Biotech Companies

12. G-Protein Coupled Receptors Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. G-Protein Coupled Receptors Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. G-Protein Coupled Receptors Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States G-Protein Coupled Receptors Market

16. China G-Protein Coupled Receptors Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abalone Bio, Inc.
  • 17.6. Abcam PLC
  • 17.7. Addex Therapeutics
  • 17.8. Becton, Dickinson and Company
  • 17.9. BioInvenu,Inc.
  • 17.10. Cisbio Bioassays SAS
  • 17.11. Confo Therapeutics
  • 17.12. Corning Incorporated
  • 17.13. Crinetics Pharmaceuticals, Inc.
  • 17.14. Domain Therapeutics SA
  • 17.15. Enzo Life Sciences, Inc.
  • 17.16. Escient Pharmaceuticals
  • 17.17. Eurofins Scientific SE
  • 17.18. Merck KGaA
  • 17.19. Molecular Devices, LLC
  • 17.20. OKYO Pharma, Limited
  • 17.21. Orion Biotechnology
  • 17.22. OSE Immunotherapeutics
  • 17.23. PerkinElmer Inc.
  • 17.24. Promega Corporation
  • 17.25. QIAGEN GmbH
  • 17.26. Septerna
  • 17.27. Sosei Group Corporation
  • 17.28. Tectonic Therapeutic
  • 17.29. Teon Therapeutics, Inc.
  • 17.30. Thermo Fisher Scientific Inc.
  • 17.31. WuXi AppTec

LIST OF FIGURES

  • FIGURE 1. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY AMINO ACID RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CHEMOKINE RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LIPID RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY MONOAMINE RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY OPSIN RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PEPTIDE RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS B SECRETIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS C METABOTROPIC GLUTAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS F FRIZZLED/TASTE 2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ORPHAN RECEPTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CNS DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RESPIRATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 191. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 215. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 216. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 223. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 224. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY RECEPTOR CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLASS A RHODOPSIN, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA G-PROTEIN COUPLED RECEPTORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)